Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.49 |
| ▸ | DTYMK | P23919 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022245 | 1.00 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22327108 | 1.00 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL5664002 | 1.00 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL8417580 | 0.93 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL8417572 | 0.93 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18952763 | 0.92 | POLG (0.50) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18790022 | 0.91 | POLB (0.50) | POLB | |
| SCHEMBL17124949 | 0.91 | POLG (0.49) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL10022896 | 0.91 | POLB (0.47) | POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1332964 | 0.91 | POLG (0.51) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025421-A1 | BASE-MODIFIED NUCLEOTIDES AS SUBSTRATES FOR TDT-BASED ENZYMATIC NUCLEIC ACID SYNTHESIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-01-27 | — | — | US | disclosed |
| US-20190112627-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-18 | — | — | US | disclosed |
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100093992-A1 | Macromolecular Nucleotide Compounds and Methods for Using the Same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7053208-B2 | Dioxetane labeled probes and detection assays employing the same | APPLERA CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-6451531-B1 | A FIRST BIOLOGICAL MOIETY SELECTED FROM THE GROUP CONSISTING OF A NUCLEIC ACID, A PEPTIDE NUCLEIC ACID, A PROTEIN, A STEROID AND A CARBOHYDRATE, SAID BIOLOGICAL MOIETY BEARING A 1,2-DIOXETANE PRECURSOR BOUND THERETO, SUCH THAT, UPON | TROPIX, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020106687-A1 | Dioxetane labeled probes and detection assays employing the same | APPLIED BIOSYSTEMS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6063574-A | Dioxetane labeled probes and detection assays employing the same | TROPIX, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5800999-A | Dioxetane-precursor-labeled probes and detection assays employing the same | TROPIX, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0251786-B1 | Alkynylamino-nucleotides | DU PONT (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151507-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0369360-A2 | Differentiation of nucleic acid segments on the basis of nucleotide differences | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4879214-A | Differentiation of nucleic acid segments on the basis of nucleotide differences | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020106687-A1 | Dioxetane labeled probes and detection assays employing the same | DCLRE1A, DDB1, CYP4X1 | POLG 913/4885POLB 826/4885P2RY2 4732/4885 |
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | NT5C3B, RNGTT, NT5C2 | POLG 166/4885POLB 21/4885P2RY2 289/4885 |
| US-20100093992-A1 | Macromolecular Nucleotide Compounds and Methods for Using the Same | NCL, PNP, NUDT1 | POLG 98/4885POLB 27/4885P2RY2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.